Top

Cancer Chemotherapy and Pharmacology

Published in:

01-12-2015 | Original Article

Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients

Authors: Ping Liu, Ying Wang, Lina Tong, Yan Xu, Weihao Zhang, Zhi Guo, Hong Ni

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2015

Abstract

Purpose

To examine whether the elevated preoperative plasma D-dimer levels show correlation with chemoresistance and poor prognosis in serous ovarian cancer patients.

Methods

Preoperative plasma D-dimer levels were measured in 125 patients with primary serous ovarian cancer (SOC).The correlations of plasma D-dimer levels with clinicopathological features, chemotherapeutic response, and survival outcome were further analyzed. Kaplan–Meier estimates were used to compute the survival functions and were compared using log-rank tests. Cox proportional-hazard regression analysis was used to evaluate the effects of D-dimer on progression-free survival (PFS) and overall survival (OS), controlling for potential confounding factors.

Results

The median follow-up period was 49 (range 5–85) months. Elevated plasma D-dimer levels were positively associated with advanced FIGO stage (P = 0.010), residual tumor size (P = 0.017), the presence of malignant ascites (P = 0.028), increased serum CA125 level (P = 0.014), and neo-adjuvant chemotherapy (P = 0.008). The patients with elevated plasma D-dimer levels had significantly higher chemoresistance rates (56.41 %) compared to the normal plasma D-dimer levels (20.93 %). Additionally, it was found by the univariate analysis that elevated plasma D-dimer levels were closely related with a low 5-year PFS rate (28.21 vs 52.33 %, P = 0.002) and a poor 5-year OS (30.77 vs 63.95 %, P < 0.001). However, after adjustment for other factors, high plasma D-dimer levels were only closely correlated with a poor 5-year OS (HR 1.901, 95 % CI 1.021–3.540; P = 0.043).

Conclusions

Elevated preoperative plasma D-dimer levels were associated with chemoresistance and poor disease outcome in serous ovarian cancer patients. Further validation of this easily available parameter as a promising prognostic biomarker for patients with SOC in prospective studies should be encouraged.

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29. doi:10.3322/caac.21208 CrossRefPubMed

Kobel M, Kalloger SE, Huntsman DG et al (2010) Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 29:203–211. doi:10.1097/PGP.0b013e3181c042b6 CrossRefPubMed

Bowtell DD (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10:803–808. doi:10.1038/nrc2946 CrossRefPubMed

Feigenberg T, Clarke B, Virtanen C et al (2014) Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. Biomed Res Int 2014:367103. doi:10.1155/2014/367103 PubMedCentralPubMed

Alkema NG, Tomar T, van der Zee AG et al (2014) Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer. Gynecol Oncol 133:591–598. doi:10.1016/j.ygyno.2014.03.557 CrossRefPubMed

Gadducci A, Cosio S, Conte PF, Genazzani AR (2005) Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol 55:153–166. doi:10.1016/j.critrevonc.2005.03.003 CrossRefPubMed

Bick RL (1992) Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 18:353–372. doi:10.1055/s-2007-1002575 CrossRefPubMed

Beer JH, Haeberli A, Vogt A et al (2002) Coagulation markers predict survival in cancer patients. Thromb Haemost 88:745–749. doi:10.1267/th02110745 PubMed

Ferrigno D, Buccheri G, Ricca I (2001) Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 17:667–673CrossRefPubMed

10.

Editorial (1986) Haemostatic abnormalities and malignant disease. Lancet 1:303–304

11.

Hillen HF (2000) Thrombosis in cancer patients. Ann Oncol 11(Suppl 3):273–276CrossRefPubMed

12.

Seitz R, Rappe N, Kraus M et al (1993) Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis 4:249–254CrossRefPubMed

13.

De Buyzere M, Philippe J, Duprez D et al (1993) Coagulation system activation and increase of D-dimer levels in peripheral arterial occlusive disease. Am J Hematol 43:91–94CrossRefPubMed

14.

Zhou YX, Yang ZM, Feng J et al (2013) High plasma D-dimer level is associated with decreased survival in patients with lung cancer: a meta-analysis. Tumour Biol 34:3701–3704. doi:10.1007/s13277-013-0953-2 CrossRefPubMed

15.

Tomimaru Y, Yano M, Takachi K et al (2006) Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J Am Coll Surg 202:139–145. doi:10.1016/j.jamcollsurg.2005.08.008 CrossRefPubMed

16.

Diao D, Wang Z, Cheng Y et al (2014) D-dimer: not just an indicator of venous thrombosis but a predictor of asymptomatic hematogenous metastasis in gastric cancer patients. PLoS ONE 9:e101125. doi:10.1371/journal.pone.0101125 PubMedCentralCrossRefPubMed

17.

Batschauer AP, Figueiredo CP, Bueno EC et al (2010) D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol 21:1267–1272. doi:10.1093/annonc/mdp474 CrossRefPubMed

18.

Sakurai M, Satoh T, Matsumoto K et al (2015) High pretreatment plasma D-dimer levels are associated with poor prognosis in patients with ovarian cancer independently of venous thromboembolism and tumor extension. Int J Gynecol Cancer 25:593–598. doi:10.1097/IGC.0000000000000415 PubMedCentralCrossRefPubMed

19.

Stender MT, Larsen TB, Sorensen HT, Thorlacius-Ussing O (2012) Preoperative plasma D-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study. J Thromb Haemost 10:2027–2031. doi:10.1111/j.1538-7836.2012.04887.x CrossRefPubMed

20.

Inanc M, Er O, Karaca H et al (2013) D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer. J BUON 18:391–397PubMed

21.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed

22.

Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715–722. doi:10.1001/jama.293.6.715 CrossRefPubMed

23.

Iversen LH, Thorlacius-Ussing O (2002) Relationship of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer. Thromb Haemost 87:402–408PubMed

24.

Unlu B, Versteeg HH (2014) Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor? Thromb Res 133(Suppl 2):S76–S84. doi:10.1016/S0049-3848(14)50013-8 CrossRefPubMed

25.

Ruf W, Mueller BM (2006) Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 32(Suppl 1):61–68. doi:10.1055/s-2006-939555 CrossRefPubMed

26.

Kasthuri RS, Taubman MB, Mackman N (2009) Role of tissue factor in cancer. J Clin Oncol 27:4834–4838. doi:10.1200/JCO.2009.22.6324 PubMedCentralCrossRefPubMed

27.

Diao D, Zhu K, Wang Z et al (2013) Prognostic value of the D-dimer test in oesophageal cancer during the perioperative period. J Surg Oncol 108:34–41. doi:10.1002/jso.23339 CrossRefPubMed

28.

Mego M, Karaba M, Minarik G et al (2015) Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients. Breast J 21:155–160. doi:10.1111/tbj.12388 CrossRefPubMed

29.

Man YN, Wang YN, Hao J et al (2015) Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism. Int J Gynecol Cancer 25:24–32. doi:10.1097/IGC.0000000000000303 CrossRefPubMed

30.

Gadducci A, Marrai R, Baicchi U et al (1997) Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer. Gynecol Oncol 66:85–88. doi:10.1006/gyno.1997.4704 CrossRefPubMed

31.

Polterauer S, Grimm C, Seebacher V et al (2009) Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist 14:979–985. doi:10.1634/theoncologist.2009-0079 CrossRefPubMed

32.

Orellana R, Kato S, Erices R et al (2015) Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells. BMC Cancer 15:290. doi:10.1186/s12885-015-1304-z PubMedCentralCrossRefPubMed

33.

Palumbo JS, Talmage KE, Massari JV et al (2007) Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 110:133–141. doi:10.1182/blood-2007-01-065995 PubMedCentralCrossRefPubMed

34.

Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S (1991) Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 87:229–236. doi:10.1172/JCI114976 PubMedCentralCrossRefPubMed

35.

Palumbo JS, Talmage KE, Massari JV et al (2005) Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:178–185. doi:10.1182/blood-2004-06-2272 CrossRefPubMed

36.

Dentali F, Ageno W, Pierfranceschi MG et al (2011) Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer. J Thromb Haemost 9:1081–1083. doi:10.1111/j.1538-7836.2011.04259.x CrossRefPubMed

Title: Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients
Authors: Ping Liu
Ying Wang
Lina Tong
Yan Xu
Weihao Zhang
Zhi Guo
Hong Ni
Publication date: 01-12-2015
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-015-2900-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2015

Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer

Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy

Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors

Oxygen carrier YQ23 can enhance the chemotherapeutic drug responses of chemoresistant esophageal tumor xenografts

Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO)

Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer